Creo Medical Group PLC Update on US Clinical Education Programme (2330U)

TIDMCREO

RNS Number : 2330U

Creo Medical Group PLC

28 March 2019

Creo Medical Group plc

("Creo" or the "Company")

Update on US Clinical Education Programme

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that additional gastrointestinal (GI) surgeons in the US have performed successful treatments in both upper and lower GI cases using Creo's Speedboat device powered by the Company's CROMA Advanced Energy platform.

Following the first successful treatment of patients in the US with Speedboat, announced in January 2019, Speedboat has now been used successfully by a further four GI surgeons. Furthermore, at a recent scientific conference, Speedboat was demonstrated during a live case to an audience of leading therapeutic GI endoscopists. During the same conference, many of these leading therapeutic endoscopists were able to get a hands-on introductory experience with Speedboat in a training environment with excellent feedback, in particular with regards to the safety profile Speedboat provides the endoscopist.

This brings the total number of doctors now trained in the US to six at five hospitals across the East and West coasts. Creo will be working very closely with these centres as further cases are carried out, along with providing a continuing Clinical Education programme.

All of these initial users of Speedboat form part of the Creo's education led strategy to identify and develop the training centres of the future, not only in the US market but also throughout our distribution network. This considered and targeted approach represents our investment in the future of the business. Speedboat is the first device of a range of GI devices to be cleared for use with the CROMA Advanced Energy platform that uniquely harnesses the use of bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation.

Dr Zacharias Tsiamoulos, Consultant in Gastroenterology and Specialist in GI Endoscopy at the East Kent University Hospitals Foundation Trust, has been overseeing training to the US surgeons on the techniques required to successfully undertake procedures utilising Speedboat. Speedboat helps to reduce the risks associated with alternative open, laparoscopic and existing endoscopic procedures, reduces the length of stay in hospital for the patient, and reduces the cost of treatment by transferring therapy from the operating theatre to the endoscopy room.

Patients have now been successfully treated using the Speedboat device in the UK, South Africa, Mainland Europe and the US.

Craig Gulliford, Chief Executive Officer of Creo, commented:

"A training-led commercialisation strategy is key to the successful roll-out of our products and we are delighted with the progress that we are making with clinicians in the US. Our Clinical Education Programme ensures that the first adopters of our technology, having been carefully mentored by our own doctors and endoscopy nurses, can deliver consistently high standards in this emerging field of surgical endoscopy, safeguarding quality control and ensuring best patient outcomes."

 
  Creo Medical Group plc 
 Richard Rees (CFO)                                                    [phone] 
 
 Cenkos Securities                                                     [phone] 
 Stephen Keys / Mark Connelly (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: [phone] or [e-mail] 
 Paul McManus                                                     Mob: [phone] 
 Helen Cresswell                                                  Mob: [phone] 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCEAKDXALSNEFF

(END) Dow Jones Newswires

March 28, 2019 03:00 ET (07:00 GMT)